Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Hydroxyurea

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

3Total
Phase 1/2 (1)
Phase 2 (1)
Phase 3 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00117572Phase 3CompletedPrimary

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

NCT00462735Phase 2Completed

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

NCT00970502Phase 1/2CompletedPrimary

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Hydroxyurea2
  • Fluorouracil2
  • Radiotherapy2
  • Cisplatin1
  • Docetaxel1

Active Sponsors

  • Johnny Kao2
  • University of Chicago1

Top Investigators

Related Conditions

  • Paranasal Sinus Neoplasms3
  • Cancer Of The Larynx3
  • Cancer Of The Oral Cavity2
  • Head And Neck Cancer1
  • Cancer Of The Head1

Activity Timeline